8/108 sources · 5 publishersUpdated Oct 15, 18:09 UTC
Iambic Therapeutics prices $150 million IPO and begins Nasdaq trading
Iambic Therapeutics priced its IPO on October 14, 2026, selling 9,375,000 shares at $16.00 each for expected gross proceeds of $150.0 million. The AI-focused drug developer was scheduled to begin trading on Nasdaq under IAM on October 15. Its shares rose above the IPO price during the debut session, although reports differ on the exact intraday price and percentage gain.
Why it matters
The offering provides Iambic with gross capital, before offering costs, to advance its drug-development pipeline. The company’s public listing gives investors access to its AI-driven therapeutics platform and early-stage cancer programs.
Key facts
- 1Iambic priced 9,375,000 common shares at $16.00 per share, with expected gross proceeds of $150.0 million before offering expenses. investing.com
- 2Underwriters received a 30-day right to acquire as many as 1,406,250 more shares at the IPO price, subject to underwriting deductions. investing.com
- 3Iambic was scheduled to start trading on the Nasdaq Global Select Market on October 15, 2026, under IAM. tradingview.com
- 4J.P. Morgan, Jefferies, BofA Securities and Citigroup served as joint book-running managers. investing.com
Open questions
- Reports disagree on the debut-session move and price: one reports shares at $18.50 after a 16% rise, while another reports a high of $17.95 and an 11% gain.
Summary written by AlphAI AI Desk from 8 of 8 sources. Not investment advice. Figures are as stated by the linked sources.